Keywords: کانگرلور; Pretreatment; Preloading; Clopidogrel; Prasugrel; Ticagrelor; Cangrelor;
مقالات ISI کانگرلور (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کانگرلور; P2Y12 inhibitors; Network meta-analysis; Cangrelor;
Cangrelor
Keywords: کانگرلور; Cangrelor; P2Y12 receptor; Stent thrombosis; Myocardial infarction; Percutaneous coronary intervention; Thienopyridine;
Cangrelor alleviates pulmonary fibrosis by inhibiting GPR17-mediated inflammation in mice
Keywords: کانگرلور; Pulmonary fibrosis; Cangrelor; GPR17; Macrophages; Inflammatory cytokines;
Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
Keywords: کانگرلور; ACS; acute coronary syndrome; ACCOAST trial; Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction trial; ACUITY; acute catheterization
Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor
Keywords: کانگرلور; cangrelor; clopidogrel; percutaneous coronary intervention; platelet reactivity; prasugrel; ticagrelor; ADP; adenosine diphosphate; AU à min; aggregation units per min; PCI; percutaneous coronary intervention;
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Keywords: کانگرلور; aspirin; cangrelor; clopidogrel; prasugrel; ticagrelor; vorapaxar; ACS; acute coronary syndromes; CABG; coronary artery bypass graft; CAD; coronary artery disease; COX; cyclooxygenase; DAPT; dual antiplatelet therapy; ICH; intracranial hemorrhage; MI; myo
Switching P2Y12 Receptor Inhibiting Therapies
Keywords: کانگرلور; P2Y12 receptor inhibitors; Switching; Clopidogrel; Prasugrel; Ticagrelor; Cangrelor;
Current status of data on cangrelor
Keywords: کانگرلور; Acute coronary syndrome; Antiplatelet therapy; Cangrelor; Coronary artery disease; P2Y12 receptor inhibition; Percutaneous coronary intervention (PCI)ACS, Acute Coronary Syndromes; ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; ARC
Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])
Keywords: کانگرلور; bivalirudin; cangrelor; CHAMPION PHOENIX; stent thrombosis; CI; confidence interval; GUSTO; Global Use of Strategies to Open Occluded Arteries; IDR; ischemia-driven revascularization; MI; myocardial infarction; mITT; modified intention-to-treat; NSTE-ACS;
GuÃa ESC 2015 sobre el tratamiento de los sÃndromes coronarios agudos en pacientes sin elevación persistente del segmento ST
Keywords: کانگرلور; Cuidados coronarios agudos; SÃndromes coronarios agudos; Angioplastia; Anticoagulación; Apixabán; Ácido acetilsalicÃlico; Aterotrombosis; Bloqueadores beta; Bivalirudina; CirugÃa de revascularización coronaria; Cangrelor; Unidad de dolor torácico;
Pharmacodynamic Effects During the Transition Between Cangrelor and Ticagrelor
Keywords: کانگرلور; antiplatelet; cangrelor; pharmacodynamics; ticagrelor; transitionADP, adenosine diphosphate; CAD, coronary artery disease; CI, confidence interval; LTA, light transmission aggregometry; MFI, mean fluorescence intensity; PGE1, prostaglandin E1; VASP, vasod
Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor–Mediated Signaling in Prasugrel-Treated Patients
Keywords: کانگرلور; cangrelor; platelet reactivity; prasugrelACS, acute coronary syndrome; ADP, adenosine diphosphate; ANCOVA, analysis of covariance; ANOVA, analysis of variance; HPR, high on-treatment platelet reactivity; MFI, mean fluorescence intensity; PCI, percutaneous
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention : Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Inter
Keywords: کانگرلور; cangrelor; IPST; PCI; stent thrombosisARC, Academic Research Consortium; BMS, bare metal stent(s); DES, drug-eluting stent(s); IDR, ischemic-driven revascularization; IPST, intra-procedural stent thrombosis; MI, myocardial infarction; NSTE-ACS, non–ST-seg
Cangrelor infusion is associated with an increased risk for bleeding: Meta-analysis of randomized trials
Keywords: کانگرلور; Cangrelor; Bleeding; Safety; Clinical trials;
Progress in Platelet Blockers: The Target is the P2Y12 Receptor
Keywords: کانگرلور; platelets; P2Y12 receptor; adenosine diphosphate; ticlopidine; clopidogrel; thienopyridines; prasugrel; ticagrelor; cangrelor; elinogrel; guidelines; perioperative period; thrombosis; bleeding; percutaneous coronary intervention; cardiac surgery; noncardi
Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
Keywords: کانگرلور; cangrelor; flow cytometry; in vivo; in vitro; laboratory rodents; mouse platelets; platelet activation; platelet reactivity; “washed blood”
ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly
Keywords: کانگرلور; ADP receptor inhibitors; perioperative period; clopidogrel; prasugrel; ticagrelor; cangrelor;
New P2Y12Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention : A Meta-Analysis
Keywords: کانگرلور; acute coronary syndrome; cangrelor; clopidogrel; elinogrel; P2Y12antagonists; percutaneous coronary intervention; prasugrelACS, acute coronary syndrome(s); CI, confidence interval; CV, cardiovascular; MACE, major adverse cardiac event(s); MI, myocardial i
New antiplatelet agents: Why they are needed
Keywords: کانگرلور; Antiplatelet agents; Prasugrel; Ticagrelor; Cangrelor; SCH 530348; Terutroban
Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect
Keywords: کانگرلور; Platelets; Angioplasty; Coronary disease; P2Y12 inhibition; Cangrelor
Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin
Keywords: کانگرلور; UFH; unfractionated heparin; A2P5P; adenosine-2,5-bisphosphate; TRAP; thrombin receptor activating peptide; PAF; platelet-activating factor; 5HT; 5-hydroxytryptamine; Platelets; Platelet aggregation inhibitors; P2 receptor; Heparin; Cangrelor;